权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Epigenetic enhancer control in maintaining homeostasis and preventing carcinogenesis in the epidermis

表观遗传增强子控制维持稳态和预防表皮癌变

基本信息

批准号：
10657490
负责人：
Brian Capell
金额：
$ 39.81万
依托单位：
UNIVERSITY OF PENNSYLVANIA
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-07-15 至 2025-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10657490
关键词：
Actinic keratosis Aging Area Biological Models Cell Count Cell physiology Cells ChIP-seq Chromatin Chromatin Remodeling Factor Clinical Data Development Disease Economic Burden Economics Enhancers Enzymes Epidermis Epigenetic Process Epithelium Functional disorder Future Gene Expression Regulation Genes Genetic Genetic Transcription Histone H3 Homeostasis Human In Vitro Incidence Individual KDM1A gene Keratin Knock-in Link Lysine Maintenance Malignant - descriptor Malignant Neoplasms Mediating Methylation Modeling Mus Mutation Neoplasms Patients Persons Pharmaceutical Preparations Phenotype Population Prevention strategy Preventive Process Proliferating Public Health Regulation Reporting Repression Role Sampling Skin Skin Cancer Technology Testing Therapeutic Transgenic Mice cancer initiation carcinogenesis chemical carcinogenesis data integration dimethylbenzanthracene epigenetic therapy epigenome epigenome editing genome-wide histone demethylase histone methylation histone methyltransferase histone modification human disease human model in vivo innovation loss of function melanoma mouse model novel therapeutics overexpression pharmacologic premalignant prevent restoration skin barrier skin disorder skin squamous cell carcinoma sun damage transcription factor transcriptome sequencing virtual

项目摘要

PROJECT ABSTRACT Epigenetics impacts all areas of cellular physiology, and epigenetic dysregulation is pervasive in human disease. Given the inherent reversibility of epigenetic changes, this presents a great opportunity for the discovery of novel therapeutics given the recent rapid development of epigenome-modifying drugs. Intriguingly, large-scale human sequencing efforts have revealed that sun-damaged, but clinically otherwise normal human skin, can harbor frequent mutations in epigenetic chromatin modifying enzymes. These include mutations that have been typically observed in cutaneous squamous cell carcinoma (cSCC), the second most common of all human malignancies, and a major economic and public health burden. Recent data suggests that these epigenetic mutations may be important drivers of malignant clone formation in the epidermis, provoking the hypothesis that proper epigenetic function is required for both maintaining epidermal homeostasis and preventing the initiation of carcinogenesis. Remarkably, despite the high incidence of both these mutations in epigenetic modifiers and cSCC, the precise mechanisms by which disruption of chromatin modifying enzymes drives the initiation of cSCC are virtually unknown. In this proposal, we will utilize multiple model systems including human patient samples and a variety of transgenic mouse models, combined with several innovative genome-wide and functional technologies in order to define the mechanistic links between chromatin regulation, transcription, epidermal cell fate, and the initiation of epidermal carcinogenesis. Collectively, these studies promise to inform both the development and utilization of epigenetic therapies in the future.

项目摘要表观遗传学影响细胞生理学的各个领域，表观遗传学失调在人类中普遍存在疾病。鉴于表观遗传变化的内在可逆性，这为鉴于最近表观基因组修饰药物的快速发展，新疗法的发现。有趣的是，大规模的人类测序工作表明，阳光受损，但临床上其他方面是正常的人类皮肤，可能存在表观遗传染色质修饰酶的频繁突变。这些突变包括通常见于皮肤鳞状细胞癌(CSCC)，是所有癌症中第二常见的人类的恶性肿瘤，以及重大的经济和公共卫生负担。最近的数据表明，这些表观遗传突变可能是表皮恶性克隆形成的重要驱动因素，从而引发假设适当的表观遗传功能是维持表皮动态平衡和防止癌变的发生。值得注意的是，尽管这两种突变在表观遗传修饰物和CSCC，染色质修饰中断的精确机制酶推动CSCC的启动几乎是未知的。在这份提案中，我们将利用多种模式系统包括人类患者样本和各种转基因小鼠模型，结合了几个创新的全基因组和功能性技术，以确定染色质调节、转录、表皮细胞命运和表皮癌变的启动。总而言之，这些研究承诺为表观遗传疗法的开发和应用提供信息未来。